{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004087","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.967502+00:00","generated_at":"2026-06-28T09:53:42.010372+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Clearside Biomedical reports Q3 loss of $0.08/share; XIPERE approval triggers $19M milestones","bullets":["XIPERE (triamcinolone acetonide) approved by FDA in Oct 2021 for macular edema associated with uveitis; first product for suprachoroidal injection.","Approval and pre-launch milestones from partners expected to provide $19M non-dilutive funding, extending cash runway into 2023.","Q3 2021 net loss $4.9M ($0.08 per share) vs $2.4M ($0.05 per share) in Q3 2020; revenue $3.1M vs $3.4M.","Cash and cash equivalents $25.2M as of Sep 30, 2021.","Phase 1/2a OASIS trial of CLS-AX (axitinib) in wet AMD completed dosing in Cohort 2; safety data expected by end of 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004087","json":"https://secwatch.observer/filing/0000950170-21-004087.json","markdown":"https://secwatch.observer/filing/0000950170-21-004087.md","text":"https://secwatch.observer/filing/0000950170-21-004087.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021004087/0000950170-21-004087-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017021004087/clsd-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:53:42.010372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}